Sugi Predict

Sugi Predict / Targets / PHOSPHO1

PHOSPHO1

Phosphoethanolamine/phosphocholine phosphatase · Q8TCT1 · PHOSPHO1 on Sugi Atlas →

3,546 patent compounds predicted against PHOSPHO1, 1,897 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2413025 SCHEMBL2413025 1.00 15/20
SCHEMBL2470520 SCHEMBL2470520 0.70 15/20
SCHEMBL2537036 SCHEMBL2537036 1.00 14/20
SCHEMBL2537991 SCHEMBL2537991 1.00 14/20
SCHEMBL6883780 SCHEMBL6883780 0.67 14/20
SCHEMBL1896513 SCHEMBL1896513 0.65 14/20
SCHEMBL1904929 SCHEMBL1904929 0.59 14/20
SCHEMBL2539354 SCHEMBL2539354 1.00 13/20
SCHEMBL6226317 SCHEMBL6226317 0.66 13/20
SCHEMBL7694465 SCHEMBL7694465 0.45 13/20
SCHEMBL7694469 SCHEMBL7694469 0.45 13/20
SCHEMBL1898397 SCHEMBL1898397 1.00 12/20
SCHEMBL2408975 SCHEMBL2408975 1.00 12/20
SCHEMBL2443755 SCHEMBL2443755 1.00 12/20
SCHEMBL2538424 SCHEMBL2538424 0.69 12/20
SCHEMBL1899006 SCHEMBL1899006 0.68 12/20
SCHEMBL1898340 SCHEMBL1898340 0.63 12/20
SCHEMBL7689966 SCHEMBL7689966 0.50 12/20
SCHEMBL2538608 SCHEMBL2538608 1.00 11/20
SCHEMBL2409405 SCHEMBL2409405 0.80 11/20

Clinical trials — most relevant to PHOSPHO1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Polyene Phosphatidylcholine in Treatment of Patients With Acute Drug-induced Liver Injury PHASE4COMPLETED
Essentiale® Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver Diseases PHASE3COMPLETED
Clinical Value of 18F-FCH PET in Localizing Parathyroid Lesions: Comparison With MIBI Scan. PHASE3COMPLETED
Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma PHASE3RECRUITING
Phospholipovit vs Placebo in Patients With Combined Hyperlipidemia PHASE2/PHASE3COMPLETED
A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease PHASE2RECRUITING
Lovaza's Effect on the Activation of Platelets PHASE2COMPLETED
Lipid Infusion in Dialysis Patients With Endotoxemia PHASE2COMPLETED
Anti-CD38 Antibody Treating APS With Thrombocytopenia PHASE2RECRUITING
Maternal Choline Supplementation and Cannabis Use During Pregnancy: Impact on Early Brain Development PHASE1RECRUITING
Choline Effects - Pre-symptomatic AD PHASE1COMPLETED
Structural Network on Prostate Cancer in the French Greater West Region nanCOMPLETED
Whole Body Bone Scan vs 18F-Choline PET/CT in Prostate Cancer nanCOMPLETED
Choline PET/CT vs. MeAIB PET/CT in Prostate Cancer nanWITHDRAWN
Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma nanACTIVE_NOT_RECRUITING
Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome nanCOMPLETED
The Effectiveness of 18F-fluorocholine Positron Emission Tomography (PET) in Detecting, Staging and Following-up Prostate Cancer nanUNKNOWN
Human Requirements for the Nutrient Choline nanCOMPLETED
Investigation of Secreted Phosphoproteins and PiP3 (Phosphoinositolphospat 3) in Sputum nanCOMPLETED
Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans nanCOMPLETED
Plaque Calcium Characterization and Ruptured Plaques nanUNKNOWN
Phospholipid Absorption of a Milk Phospholipid nanCOMPLETED
Choline Uptake Study nanCOMPLETED
Observational Study of Choline, Its Metabolites, and Phospholipids in Preterm Infants nanCOMPLETED
Synergy Between Choline and DHA nanUNKNOWN
Egg Intake, Metabolic Outcomes and Choline Levels nanRECRUITING
Variability in Human Fatty Acids Profiles Based on Blood Fractions and Metabolic Conditions nanNOT_YET_RECRUITING
Plasma and Urine TMAO Formation and Changes to Oxidized LDL After Ingestion of Different Amounts of Egg nanCOMPLETED
Acute Effects of Alpha-glycerylphosphorylcholine (A-GPC) on Lower Body Muscular Performance. nanNOT_YET_RECRUITING
Sphingo-lipotoxicity and Trans-differentiation of Adipose Tissue in Obesity (SFINGOTRANS) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PHOSPHO1 binder may also engage these)

ProteinNameSimilarity
Q8R2H9 — 1.000 Q8R2H9 →
NT5M 5'(3')-deoxyribonucleotidase, mitochondrial 0.956 landscape →
Q8VCE6 — 0.955 Q8VCE6 →
Q2T9S4 — 0.945 Q2T9S4 →
A6NDG6 — 0.943 A6NDG6 →
TRPM5 Transient receptor potential cation channel subfamily M member 5 0.940 landscape →
A6QQ24 — 0.939 A6QQ24 →
D3ZDK7 — 0.939 D3ZDK7 →
Q8CHP8 — 0.938 Q8CHP8 →
Q8NE01 — 0.938 Q8NE01 →
Q3ZBF9 — 0.938 Q3ZBF9 →
Q9BQD7 — 0.937 Q9BQD7 →
Q5F4B1 — 0.937 Q5F4B1 →
P60487 — 0.937 P60487 →
Q9R1U9 — 0.936 Q9R1U9 →
O73884 — 0.936 O73884 →
Q96G46 — 0.935 Q96G46 →
Q9Y644 — 0.934 Q9Y644 →
Q8VD52 — 0.933 Q8VD52 →
A5PK51 — 0.932 A5PK51 →
O09009 — 0.931 O09009 →
Q96FB5 — 0.931 Q96FB5 →
Q86VU5 — 0.930 Q86VU5 →
Q96GD0 — 0.930 Q96GD0 →
Q9DBC0 — 0.930 Q9DBC0 →
P52850 — 0.930 P52850 →
Q1JPJ0 — 0.929 Q1JPJ0 →
O97583 — 0.929 O97583 →
P23726 — 0.929 P23726 →
COLGALT1 Procollagen galactosyltransferase 1 0.929 landscape →